Long-Term Suppressive Effect of Octreotide on Progression of Metastatic Gastrinoma with Multiple Endocrine Neoplasia Type 1: Seven-Year Follow up

• Published in: Internal Medicine Vol. 49; no. 15; pp. 1557 - 1563
• Main Authors: Yamaguchi, Megu, Yamada, Yuya, Hosokawa, Yoshiya, Iwamoto, Ryuya, Tamba, Sachiko, Ihara, Arisa, Yamamoto, Koji, Hoshida, Yoshihiko, Matsuzawa, Yuji
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society of Internal Medicine 01.01.2010
• Subjects: Adult; Disease Progression; Female; Follow-Up Studies; gastrinoma; Gastrinoma - diagnosis; Gastrinoma - drug therapy; Humans; MEN1; Multiple Endocrine Neoplasia Type 1 - diagnosis; Multiple Endocrine Neoplasia Type 1 - drug therapy; octreotide; Octreotide - administration & dosage; Pancreatic Neoplasms - diagnosis; Pancreatic Neoplasms - drug therapy; somatostatin receptor; Time Factors
• ISSN: 0918-2918; 1349-7235
• DOI: 10.2169/internalmedicine.49.3607

A 30-year-old woman had a history of prolactinoma and primary hyperparathyroidism. She was diagnosed as having multiple endocrine neoplasia type 1 with gastrinoma and liver metastases. Octreotide therapy was started and the serum gastrin level decreased immediately. Octreotide continued to suppress gastrin secretion over the next 7 years. The Ki67/MIB1 proliferation index of this tumor was only 0.5 % and somatostatin receptor (SSTR) 2 expression was very strong in both 2002 and 2009. This case suggests the importance of investigating the Ki67/MIB1 index and SSTR expression in patients with metastatic gastrinoma.